

A novel 3D liver organoid platform technology for drug toxicology screening and cell therapy

We have created a stem cell-derived 3D liver organoid platform that replicates the architecture, cellular complexity, and key functions of the human liver. The team is currently advancing this unlimited, scalable, and cost-efficient technology for drug toxicology assessment and rescue of liver functions. The planned spin-out (Q2 2026) has exclusive IP (Patent WO2022101675A1) for all applications.

Market assessment

- Drug toxicology screening: 68b USD
- Cell therapy: 85b USD

Current focus

Drug toxicology screening
- Establishing production site

Cell therapy
- Bleeding disorders

Competitive advantages

Drug toxicology
- Eliminates animal testing (NAMs)
- Complex & high-throughput
- Acute & chronic exposure
- Patient-specific
- Digital liver model

Cell therapy
- Rescue all liver functions (from hereditary to end-stage liver disease)
- Autologous & off-the-shelf
- Re-administrable
- First-in-class

Development stage

Drug toxicology
- Validated

Cell therapy
- Preclinical

Needs

Drug toxicology
- Investor funding

Cell therapy
- Collaboration & partnership
- Expert network

Project leader
Giacomo Roman; MSc
giacomo.roman@medisin.uio.no

Project coordinator
Erlend Ragnhildstveit; CEO
Bioselera

Team members
- Benedicte Stavik; PhD
- Maria E. Chollet; MD, PhD
- Per Morten Sandset; MD, PhD
- Gareth Sullivan; PhD, CSO Occambio
- David Sønstebø; Co-founder Occambio
- Christian Qvigstad; MD, PhD
- Anne Ulvestad; CEO Innosiamo

SPARK NORWAY

OSLO UNIVERSITY HOSPITAL

UNIVERSITY OF OSLO